Drugs / pegylated endostatin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01527864 | May 2011 → Dec 2012 | non-small cell lung carcinoma | Protgen Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegylated endostatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01527864 ↗ |
| Route | Intravenous | “PEGylated endostatin at a dose of 10 mg/m2 intravenously every weeks” NCT01527864 ↗ |